Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. 2011

Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
Laboratory of Physiologic Studies, National Institutes of Health, Bethesda, MD 20892, USA.

Ischemia/reperfusion (I/R) is a pivotal mechanism of liver damage after liver transplantation or hepatic surgery. We have investigated the effects of cannabidiol (CBD), the nonpsychotropic constituent of marijuana, in a mouse model of hepatic I/R injury. I/R triggered time-dependent increases/changes in markers of liver injury (serum transaminases), hepatic oxidative/nitrative stress (4-hydroxy-2-nonenal, nitrotyrosine content/staining, and gp91phox and inducible nitric oxide synthase mRNA), mitochondrial dysfunction (decreased complex I activity), inflammation (tumor necrosis factor α (TNF-α), cyclooxygenase 2, macrophage inflammatory protein-1α/2, intercellular adhesion molecule 1 mRNA levels; tissue neutrophil infiltration; nuclear factor κB (NF-κB) activation), stress signaling (p38MAPK and JNK), and cell death (DNA fragmentation, PARP activity, and TUNEL). CBD significantly reduced the extent of liver inflammation, oxidative/nitrative stress, and cell death and also attenuated the bacterial endotoxin-triggered NF-κB activation and TNF-α production in isolated Kupffer cells, likewise the adhesion molecule expression in primary human liver sinusoidal endothelial cells stimulated with TNF-α and attachment of human neutrophils to the activated endothelium. These protective effects were preserved in CB2 knockout mice and were not prevented by CB1/2 antagonists in vitro. Thus, CBD may represent a novel, protective strategy against I/R injury by attenuating key inflammatory pathways and oxidative/nitrative tissue injury, independent of classical CB1/2 receptors.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D002185 Cannabidiol Compound isolated from Cannabis sativa extract. 1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-,Epidiolex
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015427 Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA. Ischemia-Reperfusion Injury,Injury, Ischemia-Reperfusion,Injury, Reperfusion,Reperfusion Damage,Damage, Reperfusion,Injury, Ischemia Reperfusion,Ischemia Reperfusion Injury,Ischemia-Reperfusion Injuries,Reperfusion Damages,Reperfusion Injuries
D016923 Cell Death The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability. Death, Cell

Related Publications

Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
February 2017, International immunopharmacology,
Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
September 2022, Journal of materials chemistry. B,
Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
July 2022, International urology and nephrology,
Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
January 2015, Evidence-based complementary and alternative medicine : eCAM,
Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
January 2015, Experimental and therapeutic medicine,
Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
January 2021, Evidence-based complementary and alternative medicine : eCAM,
Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
April 2021, Human & experimental toxicology,
Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
August 2010, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
January 2013, International journal of clinical and experimental pathology,
Partha Mukhopadhyay, and Mohanraj Rajesh, and Béla Horváth, and Sándor Bátkai, and Ogyi Park, and Galin Tanchian, and Rachel Y Gao, and Vivek Patel, and David A Wink, and Lucas Liaudet, and György Haskó, and Raphael Mechoulam, and Pál Pacher
May 2015, Journal of biomedical research,
Copied contents to your clipboard!